Mode
Text Size
Log in / Sign up

Renal denervation value framework prioritizes efficacy and safety for Chinese hospital procurement

Renal denervation value framework prioritizes efficacy and safety for Chinese hospital procurement
Photo by Ritu Chauhan / Unsplash
Key Takeaway
Consider this value framework as a structured tool for RDN procurement decisions, but recognize it is expert-opinion based and unvalidated.

This narrative review describes the development of a comprehensive value assessment framework for renal denervation (RDN) therapy in Chinese hospitals. The framework was constructed using a multi-criteria decision analysis approach, with criteria weights determined by expert input. At the first level, efficacy received the highest weight (23.26%), followed by safety (21.83%), qualification and suitability (16.84%), patient value (15.18%), innovation (10.65%), management value (6.22%), and cost (6.01%). The authors intend this framework to support procurement reviews and decisions for RDN devices in Chinese hospitals.

The review does not report any primary clinical data, sample size, or comparator. It is a methodological paper outlining a decision tool rather than a systematic synthesis of clinical evidence. The framework's weights reflect expert opinion and may not generalize to other settings. No limitations are explicitly acknowledged by the authors.

Clinicians should interpret this framework as a structured approach to evaluating RDN devices for hospital formularies, but its practical utility depends on local validation and integration with clinical evidence. The framework does not replace direct evidence on RDN efficacy or safety in hypertensive patients.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
ObjectiveRenal denervation (RDN) therapy is an innovative interventional therapy for patients with refractory hypertension and antihypertensive drug intolerance. In China, four RDN products were approved by National Medical Products Administration. This study aims to construct a comprehensive value assessment framework for RDN therapy to support the rational selection and application in Chinese hospitals.MethodsMultiple Criteria Decision Analysis (MCDA) approach was used to develop the framework. We conducted a literature review and focus group interviews to identify the list of criteria that should be included in the framework. Then, the Delphi method was applied to refine the framework. With the engagement of cardiologists and non-clinical professionals from hospitals in different regions, weights were given to each criterion by the Analytic Hierarchy Process.ResultsThe comprehensive value assessment framework for RDN therapy consists of three levels of criteria in seven domains, including seven criteria at the first level, 16 secondary criteria and 30 sub-criteria at the third level. The distribution of criteria weights at the first level is: efficacy (23.26%), safety (21.83%), qualification and suitability (16.84%), patient value (15.18%), innovation (10.65%), management value (6.22%), and cost (6.01%). The prioritized domains are efficacy, safety, qualification and suitability.ConclusionThe development of a comprehensive value assessment framework for RDN can serve as a reliable and scientific tool to support the procurement reviews and decisions for RDN devices in Chinese hospitals.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.